PVCT — Provectus Biopharmaceuticals Balance Sheet
0.000.00%
- $26.86m
- $29.07m
- $0.62m
Annual balance sheet for Provectus Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.097 | 0.683 | 0.022 | 0.077 | 0.307 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.004 | 0.005 | 0 | 0 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.424 | 3.44 | 1.9 | 1.36 | 0.977 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.166 | 0.071 | 0.138 | 0.084 | 0.029 |
| Net Intangible Assets | |||||
| Total Assets | 0.589 | 3.51 | 2.04 | 1.45 | 1.01 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 30.7 | 7.7 | 8.19 | 9.02 | 6.98 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 30.8 | 7.7 | 8.27 | 9.04 | 6.97 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -30.2 | -4.19 | -6.23 | -7.59 | -5.96 |
| Total Liabilities & Shareholders' Equity | 0.589 | 3.51 | 2.04 | 1.45 | 1.01 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |